Overview

Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.

Status:
Completed

Trial end date:
2018-07-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine the effectiveness of Ranibizumab 0.5 mg or 1.0 mg in subjects who were previously treated with Bevacizumab and subsequently switched to Aflibercept. These subjects have demonstrated a sub-optimal therapeutic response to the previous therapies; therefore, the study aims to see if Ranibizumab may have a greater treatment effect.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Northern California Retina Vitreous Associates

Collaborator:

Genentech, Inc.

Treatments:

Ranibizumab